Awards & Advancement

Gong joins Premier Research

Wednesday, December 21, 2011 12:32 PM

Premier Research Group has named Hua Gong executive director of medical diagnostics. In this role, Gong will be responsible for overseeing the in vitro diagnostics (IVD) business within the company.

More... »

Excelimmune raises $12 million to develop infectious disease programs

Tuesday, December 20, 2011 12:20 PM

Excelimmune has raised $12 million from a private investor. Proceeds will be used by Excelimmune to develop its infectious disease programs, including Staphguard, a human recombinant polyclonal antibody (HRPA) candidate against methicillin-resistant Staphylococcus aureus (MRSA), and to expand its discovery programs to new disease targets beyond infectious diseases through its antibody screening technology.

More... »

ImmusanT secures $20 million in Series A financing

Friday, December 16, 2011 08:15 AM

ImmusanT has raised $20 million in Series A financing from Vatera Healthcare Partners to advance development of the biotechnology company's immunotherapeutic vaccine Nexvax2, companion diagnostic and monitoring tool for celiac disease. The proceeds will fund the Nexvax2 therapeutic and diagnostic development plan to the point of demonstrating proof-of-concept. ImmusanT expects to initiate the next clinical trial in early 2012.

More... »

Cerulean secures $15 million in Series D financing

Thursday, December 15, 2011 03:56 PM

Cerulean Pharma has closed a $15 million Series D financing with participation from new investor, CVF, an affiliate of Henry Crown of Chicago, Illinois, as well as full participation from all other existing investors, including Polaris Venture Partners, Venrock, Lilly Ventures, Lux Capital, and Bessemer Venture Partners. In conjunction with the closing of the financing, Robert Paull, a co-founder and managing partner at Lux Capital, has joined Cerulean's board of directors as the director designated jointly by Lux Capital and CVF.

More... »

AVI BioPharma names senior VP

Tuesday, December 13, 2011 12:18 PM

AVI BioPharma has named Jayant Aphale, Ph.D., senior vice president of technical operations. Aphale will have responsibility for all of AVI's internal and outsourced manufacturing activities, with an emphasis on technology transfer, scale-up, CMC compliance, CMC regulatory issues, and CMC project management from initial development through commercial production.

More... »

Catabasis receives $8 million in Series A extension financing

Tuesday, December 13, 2011 09:41 AM

Catabasis Pharmaceuticals has received an additional $8 million in Series A financing, bringing the total amount raised to $47.6 million. All current investors participated in the financing, including SV Life Sciences, Clarus Ventures, MedImmune Ventures and Advanced Technology Ventures. The new funding will be used to accelerate the development of CAT-2003, the company’s omega-3 conjugated compound for patients with severe hypertriglyceridemia, and move the compound into the clinic in 2012.

More... »

Benedyk joins Amarantus as strategic advisor

Tuesday, December 13, 2011 09:29 AM

Amarantus BioSciences has named Mark J. Benedyk, PhD, strategic advisor effective immediately. In this role, he will support the company with strategy and business development issues.

More... »

Wheeler joins Acetylon

Monday, December 12, 2011 02:20 PM

Acetylon Pharmaceuticals has named Catherine A. Wheeler, MD, vice president, clinical development. Wheeler will have responsibility for all clinical development functions of the company, including current and future clinical trials of Acetylon’s HDAC6 selective drug candidate, ACY-1215, in multiple myeloma as well as other potential hematologic and solid tumor disease indications. She will also lead the clinical development of future drug candidates in inflammatory and neurodegenerative diseases.

More... »

Mylan names president of Dey Pharma

Monday, December 12, 2011 01:50 PM

Mylan has named John Thievon president of Dey Pharma, Mylan's pharmaceutical business.

More... »

Groove Biopharma closes $6 million Series B financing round

Monday, December 12, 2011 11:41 AM

Groove Biopharma has raised $6 million in a Series B financing. Participating in the financing was Alexandria Venture Investments, ARCH Venture Partners, OVP Venture Partners, Versant Ventures, and WRF Capital. Proceeds from the financing will be used to bring forward development of Groove’s proprietary MGB-based miRNA delivery platform. The company has also promoted David L. McElligott, Ph.D. to chief scientific officer.

More... »